We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: IL-17F
MedXY News
EnglishTag

IL-17F

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationcritical carebiomarkersartificial intelligencetype 1 diabetesclinical trialsHypertensiononcologyCardiologyMortalitypublic healthcardiovascular diseasediabetesAlzheimer's diseaseepidemiologybreast cancer

Latest news

Tag

Sonelokimab: A Promising Dual IL-17A/F Nanobody for Moderate-to-Severe Hidradenitis Suppurativa
Allergy & Immunologyclinical trialhidradenitis suppurativa

Sonelokimab: A Promising Dual IL-17A/F Nanobody for Moderate-to-Severe Hidradenitis Suppurativa

By MedXY|Oct 16, 2026

The phase 2 MIRA trial shows sonelokimab, an IL-17A/F-inhibiting nanobody, significantly improves outcomes in moderate-to-severe hidradenitis suppurativa with good tolerability compared to placebo.

Dual IL-17A/F Blockade and Increased Candidiasis Risk
Clinical UpdatesbimekizumabIL-17A

Dual IL-17A/F Blockade and Increased Candidiasis Risk

By MedXY|Jul 31, 2025

Blocking both IL-17A and IL-17F impairs neutrophil migration, reducing antifungal defense and raising candidiasis risk in patients on bimekizumab, according to in vitro evidence.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Cardiology
Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models